Delivering next-generation treatments for back of the eye disorders, with focus on diabetic eye disease

Preclinical evaluation of an anti-alpha5beta1 integrin antibody as a novel anti-angiogenic agent.

Ramakrishnan,V., Bhaskar,V., Law,D.A., Wong,M.H., DuBridge,R.B., Breinberg,D., O'Hara,C., Powers,D.B., Liu,G., Grove,J., Hevezi,P., Cass,K.M., Watson,S., Evangelista,F., Powers,R.A., Finck,B., Wills,M., Caras,I., Fang,Y., McDonald,D., Johnson,D., Murray,R., and Jeffry,U. 2006. Preclinical evaluation of an anti-alpha5beta1 integrin antibody as a novel anti-angiogenic agent. J. Exp. Ther. Oncol. 5, 273-286.